Breast Cancer

At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences.

To universally recommend breast irradiation for all women after excision of DCIS lesions ignores information now available to us that can spare the majority of women with DCIS the downsides of RT, but be applied in the treatment of DCIS patients at greater risk for invasive disease.

Low levels of cytotoxic stromal tumor-infiltrating lymphocytes are predictive of benefit derived from antibody- vs small molecule–based drug approaches to HER2-positive metastatic breast cancer.

Comprehensive sequencing for all breast cancer genes may provide complete relevant genetic information for Ashkenazi Jewish patients.

Breast cancer subtypes generally did not respond differently to radiotherapy following breast-conserving surgery, according to long-term follow-up of a randomized trial.

Researchers have discovered new associations between breast and ovarian cancer and genes that had not been previously detected, and which may help guide treatment decisions in the future.

The FDA Oncologic Drugs Advisory Committee has unanimously voted to recommend approval of the trastuzumab biosimilar MYL-1401O for the treatment of HER2-positive breast cancer.

The FDA has approved neratinib (Nerlynx) for use as extended adjuvant treatment in adult patients with early-stage HER2-positive breast cancer.

The use of bisphosphonates was not associated with a decrease in the incidence of breast cancer in postmenopausal women, contrary to hypothesis.

The 70-gene test could aid clinicians and patients in determining the optimal treatment course for breast cancer patients with a very low risk of death from the disease.

A 46-year-old woman had a routine screening mammogram that showed new calcifications in the posterior left breast. A diagnostic mammogram showed several small punctate calcifications, and a 6-month interval follow-up was recommended.

T-DM1 administered for 12 weeks with or without endocrine therapy yields good rates of pathologic complete response in women with HER2-positive/hormone receptor–positive breast cancer, according to a new randomized trial.

A 70-gene expression score can identify women with indolent breast cancer at “ultralow” risk, according to a new study. Women with such a score have extremely low risk of disease-specific mortality over 20 years without systemic therapy.

A recent study shows that many women with early-stage breast cancer are still undergoing unnecessary chest CT, despite NCCN recommendations.

A new study that used prospective data provides estimates of cancer risk based on BRCA1/2 mutation status and shows the potential role of family history and the location of the mutation in assessing risk.

A new clinical trial is recruiting to determine whether a breath testing device can aid in the diagnosis of breast cancer.

Replacing a cyclophosphamide-based regimen with oral capecitabine does not sacrifice efficacy in adjuvant therapy for early breast cancer, and improves quality of life, according to a new study.

In this interview we discuss some of the novel therapeutics in development for HER2-amplified breast cancer.

A biosimilar to trastuzumab known as CT-P6 showed equivalent efficacy and similar toxicity to the original agent in patients with HER2-positive breast cancer.

Limiting Medicaid enrollment has the potential for negative health impacts, in particular among low-income women with a diagnosis of breast cancer, according to a new study.

Results from a nationwide clinical trial, which were presented at the 2017 ASCO Annual Meeting, indicate that adding pembrolizumab to standard therapy before surgery offers the potential for improving outcomes in this patient population.

The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy.

Patients with HER2-negative breast cancer with residual invasive disease following neoadjuvant chemotherapy benefit from adjuvant treatment with capecitabine.

The use of a four-gene signature identified a series of subgroups of triple-negative breast cancer, including one subtype that was responsive to platinum-based chemotherapy in the metastatic setting.

For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy.

Dual HER2 blockade was superior to single blockade in postmenopausal women with HER2-positive, HR-positive metastatic breast cancer.

The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease–free survival in patients with HER2-positive early breast cancer.

The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective response rate among 40 heavily pretreated women with estrogen receptor (ER)-positive, HER2-negative breast cancer.

Adding ipatasertib to first-line paclitaxel modestly improved progression-free survival in women with triple-negative breast cancer.

The PARP inhibitor olaparib increases progression-free survival and improves quality of life in BRCA-mutated HER2-negative metastatic breast cancer patients.